Core Viewpoint - UBI, a major shareholder of Shenlian Bio, plans to reduce its stake in the company to fund clinical trials and commercialization of its Alzheimer's peptide vaccine and related manufacturing base in China [1] Shareholder Reduction Plan - UBI intends to reduce its holdings by selling 4,106,440 shares through centralized bidding on the Shanghai Stock Exchange, which represents up to 1.00% of the total shares [1] - Additionally, UBI plans to sell 8,212,880 shares via block trading, accounting for up to 2.00% of the total shares [1] - The share reduction will occur within three months after a 15 trading day period following the announcement and will be at market price, not lower than the initial public offering price [1]

智通财经APP讯，申联生物(688098.SH)发布公告，美国联合生物医药公司(UNITED BIOMEDICAL, INC. 简称"UBI")因推进其阿尔茨海默症合成肽疫苗等原研创新药的临床试验、商业化布局及与中国的 合作伙伴加速与合成肽有关的生产制造基地的建设等而需资金投入，拟自公告披露之日起15个交易日之 后的3个月内以通过上海证券交易所交易系统以集中竞价交易方式减持公司股份410.64万股，不超过公 司股份总数的1%;以大宗交易方式减持公司股份821.29万股，不超过公司股份总数的2%。 ...